BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//Bordeaux Institute of Oncology - ECPv6.17.3.1//NONSGML v1.0//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-ORIGINAL-URL:https://www.bricbordeaux.com/en/
X-WR-CALDESC:Events for Bordeaux Institute of Oncology
REFRESH-INTERVAL;VALUE=DURATION:PT1H
X-Robots-Tag:noindex
X-PUBLISHED-TTL:PT1H
BEGIN:VTIMEZONE
TZID:Europe/Paris
BEGIN:DAYLIGHT
TZOFFSETFROM:+0100
TZOFFSETTO:+0200
TZNAME:CEST
DTSTART:20240331T010000
END:DAYLIGHT
BEGIN:STANDARD
TZOFFSETFROM:+0200
TZOFFSETTO:+0100
TZNAME:CET
DTSTART:20241027T010000
END:STANDARD
BEGIN:DAYLIGHT
TZOFFSETFROM:+0100
TZOFFSETTO:+0200
TZNAME:CEST
DTSTART:20250330T010000
END:DAYLIGHT
BEGIN:STANDARD
TZOFFSETFROM:+0200
TZOFFSETTO:+0100
TZNAME:CET
DTSTART:20251026T010000
END:STANDARD
BEGIN:DAYLIGHT
TZOFFSETFROM:+0100
TZOFFSETTO:+0200
TZNAME:CEST
DTSTART:20260329T010000
END:DAYLIGHT
BEGIN:STANDARD
TZOFFSETFROM:+0200
TZOFFSETTO:+0100
TZNAME:CET
DTSTART:20261025T010000
END:STANDARD
END:VTIMEZONE
BEGIN:VEVENT
DTSTART;TZID=Europe/Paris:20250513T093000
DTEND;TZID=Europe/Paris:20250513T103000
DTSTAMP:20250428T132916Z
CREATED:20250422T144410Z
LAST-MODIFIED:20250428T132916Z
UID:49188-1747128600-1747132200@www.bricbordeaux.com
SUMMARY:Invited Seminar Bruno Segui -13-05-2025
DESCRIPTION:Pr. Bruno Segui \, invited by Majid Khatib\, team 2 Reprograming tumor activitY and associaTed MicroenvironmEnt (Rytme).\nCo-head of the team MELASPHINX: Ceramide metabolism in melanoma: from basic mechanisms to immunotherapy in the Toulouse Cancer Research Center (CRCT) \nTitle : TNF blockade with certolizumab\, but not infliximab\, improves efficacy of anti-PD-1 and anti-CTLA-4 combination in melanoma \n  \nAbstract \nThe combination of anti-PD-1 and anti-CTLA-4 boosts the anti-cancer immune response in patients with advanced melanoma. However\, 60% of patients fail to respond or relapse early after induction\, and 95% develop immune-related adverse events (irAEs) such as colitis\, which can be treated with infliximab\, a tumour necrosis factor-alpha inhibitor (TNFi). The impact of TNFi on immune and clinical responses remains to be elucidated. Here we provide evidence that TNF blockade can improve the response to the anti-PD-1 and anti-CTLA-4 combination not only in mice but also in patients enrolled in a phase 1b clinical trial (TICIMEL\, NTC03293784). However\, certolizumab\, but not infliximab\, strongly stimulates immune and therapeutic responses to ICI. Mechanistically\, we have shown that the IgG1 Fc fragment of infliximab impairs the ability of TNF blockade to stimulate the efficacy of ICI therapy. When combined with ICI\, certolizumab decreased the proportion of regulatory T cells (Tregs) and exhausted T cells\, while increasing the proportion of effector T cells in tumors as assessed by single-cell RNA sequencing and spectral flow cytometry. In conclusion\, our study shows that TNF impairs the immune response to melanoma and that the type of TNFi must be well selected to improve the efficacy of ICI in melanoma.        \n  \nBruno Ségui  \nCV overview: \n2000: PhD in human pathophysiology (Toulouse University). \n2000-2002: Postdoctoral position (University College London\, UK). \n2006: HDR (Toulouse University). \n2002-2011: Assistant Professor of Immunology\, Faculty of Pharmacy (Toulouse III). \nSince 2011: Professor of Cell Biology\, Faculty of Pharmacy (Toulouse III). \nResearch activity in the Cancer Research Center of Toulouse (CRCT). \nSince 2019: Deputy Director of the CARe graduate school on Cancer Aging and Rejuvenation. \nSince 2021: Team leader of MELASPHINX at the Cancer Research Center of Toulouse\, \nco-PI: Dr. N. Andrieu-Abadie.  \n  \nOverview of research activities: \nOver the last 25 years\, I have been studying the signalling pathways triggered by some members of the TNF receptor superfamily\, including CD40\, Fas/CD95 and TNFR1/CD120a. In this context\, we have highlighted the role of sphingolipids in the modulation of both apoptosis and immune responses (Ségui et al.\, J. Biol. Chem.\, 1999; Ségui et al\, J. Clin. Invest. 2001; Montfort et al.\, J. Immunol. 2009; Lafont et al.\, Cell Death Differ. 2010). More recently\, we have shown that TNF blockade enhances the CD8 T cell-dependent immune response (Bertrand et al.\, Cancer Res. 2015) and overcomes the resistance to anti-PD-1 (Bertrand et al.\, Nat. Commun. 2017) in mouse melanoma models. Mechanistically\, TNF triggers the activation-induced cell death of CD8+ tumour-infiltrating lymphocytes. We have translated our concept into the clinic in advanced melanoma patients\, where we have shown that two triple therapies combining TNF blockers (infliximab or certolizumab) with anti-PD-1 (nivolumab) and anti-CTLA-4 (certolizumab) are safe for patients\, with promising signs of efficacy in the certolizumab cohort (Montfort et al.\, Clin. Cancer Res 2021). Moreover\, Elevated plasma TNF and enriched TNF pathways in T cells are associated with poorer clinical outcome in patients with advanced melanoma\, reinforcing the notion that TNF may dampen the efficacy of immune checkpoint inhibitors (Virazels et al.\, Int J Cancer\, in press).      \n 
URL:https://www.bricbordeaux.com/en/event/invited-seminar-bruno-segui-12-05-2025/
LOCATION:Salle de conférence BBS (Bordeaux Biologie Santé)\, 2 rue Dr Hoffmann Martinot\, Bordeaux
CATEGORIES:Meetings,Scientific seminars
ATTACH;FMTTYPE=image/jpeg:https://cdn-bricbordeaux.onlc.eu/wp-content/uploads/2025/04/seminar-bruno-segui-2025-05-13.jpg
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=Europe/Paris:20250513T093000
DTEND;TZID=Europe/Paris:20250513T103000
DTSTAMP:20250428T133528Z
CREATED:20250428T133528Z
LAST-MODIFIED:20250428T133528Z
UID:49259-1747128600-1747132200@www.bricbordeaux.com
SUMMARY:Invited Seminar - Bruno Segui - 13-05-2025
DESCRIPTION:Pr. Bruno Segui \, invited by Majid Khatib\, team 2 Reprograming tumor activitY and associaTed MicroenvironmEnt (Rytme).\nCo-head of the team MELASPHINX: Ceramide metabolism in melanoma: from basic mechanisms to immunotherapy in the Toulouse Cancer Research Center (CRCT) \nTitle : TNF blockade with certolizumab\, but not infliximab\, improves efficacy of anti-PD-1 and anti-CTLA-4 combination in melanoma \n  \nAbstract \nThe combination of anti-PD-1 and anti-CTLA-4 boosts the anti-cancer immune response in patients with advanced melanoma. However\, 60% of patients fail to respond or relapse early after induction\, and 95% develop immune-related adverse events (irAEs) such as colitis\, which can be treated with infliximab\, a tumour necrosis factor-alpha inhibitor (TNFi). The impact of TNFi on immune and clinical responses remains to be elucidated. Here we provide evidence that TNF blockade can improve the response to the anti-PD-1 and anti-CTLA-4 combination not only in mice but also in patients enrolled in a phase 1b clinical trial (TICIMEL\, NTC03293784). However\, certolizumab\, but not infliximab\, strongly stimulates immune and therapeutic responses to ICI. Mechanistically\, we have shown that the IgG1 Fc fragment of infliximab impairs the ability of TNF blockade to stimulate the efficacy of ICI therapy. When combined with ICI\, certolizumab decreased the proportion of regulatory T cells (Tregs) and exhausted T cells\, while increasing the proportion of effector T cells in tumors as assessed by single-cell RNA sequencing and spectral flow cytometry. In conclusion\, our study shows that TNF impairs the immune response to melanoma and that the type of TNFi must be well selected to improve the efficacy of ICI in melanoma.        \n  \n📆 Tuesday\, May 13 9:30 a.m.\n📌 Amphi BBS (Bordeaux Biologie Santé) 2 rue du Dr Hoffmann Martinot \n  \nBruno Ségui  \nCV overview: \n2000: PhD in human pathophysiology (Toulouse University). \n2000-2002: Postdoctoral position (University College London\, UK). \n2006: HDR (Toulouse University). \n2002-2011: Assistant Professor of Immunology\, Faculty of Pharmacy (Toulouse III). \nSince 2011: Professor of Cell Biology\, Faculty of Pharmacy (Toulouse III). \nResearch activity in the Cancer Research Center of Toulouse (CRCT). \nSince 2019: Deputy Director of the CARe graduate school on Cancer Aging and Rejuvenation. \nSince 2021: Team leader of MELASPHINX at the Cancer Research Center of Toulouse\, \nco-PI: Dr. N. Andrieu-Abadie.  \n  \nOverview of research activities: \nOver the last 25 years\, I have been studying the signalling pathways triggered by some members of the TNF receptor superfamily\, including CD40\, Fas/CD95 and TNFR1/CD120a. In this context\, we have highlighted the role of sphingolipids in the modulation of both apoptosis and immune responses (Ségui et al.\, J. Biol. Chem.\, 1999; Ségui et al\, J. Clin. Invest. 2001; Montfort et al.\, J. Immunol. 2009; Lafont et al.\, Cell Death Differ. 2010). More recently\, we have shown that TNF blockade enhances the CD8 T cell-dependent immune response (Bertrand et al.\, Cancer Res. 2015) and overcomes the resistance to anti-PD-1 (Bertrand et al.\, Nat. Commun. 2017) in mouse melanoma models. Mechanistically\, TNF triggers the activation-induced cell death of CD8+ tumour-infiltrating lymphocytes. We have translated our concept into the clinic in advanced melanoma patients\, where we have shown that two triple therapies combining TNF blockers (infliximab or certolizumab) with anti-PD-1 (nivolumab) and anti-CTLA-4 (certolizumab) are safe for patients\, with promising signs of efficacy in the certolizumab cohort (Montfort et al.\, Clin. Cancer Res 2021). Moreover\, Elevated plasma TNF and enriched TNF pathways in T cells are associated with poorer clinical outcome in patients with advanced melanoma\, reinforcing the notion that TNF may dampen the efficacy of immune checkpoint inhibitors (Virazels et al.\, Int J Cancer\, in press).      \n 
URL:https://www.bricbordeaux.com/en/event/invited-seminar-bruno-segui-13-05-2025/
LOCATION:Salle de conférence BBS (Bordeaux Biologie Santé)\, 2 rue Dr Hoffmann Martinot\, Bordeaux
CATEGORIES:Meetings,Scientific seminars
ATTACH;FMTTYPE=image/jpeg:https://cdn-bricbordeaux.onlc.eu/wp-content/uploads/2025/04/seminar-bruno-segui-2025-05-13.jpg
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=Europe/Paris:20250514T150000
DTEND;TZID=Europe/Paris:20250514T160000
DTSTAMP:20250428T092433Z
CREATED:20250428T092433Z
LAST-MODIFIED:20250428T092433Z
UID:49248-1747234800-1747238400@www.bricbordeaux.com
SUMMARY:Invited seminar - Thomas Bertero - 14-05-2025
DESCRIPTION:Invited seminar by Violaine Moreau\, Team 3\, Liver Cancers and Tumor Invasion and Isabelle Sagot\, Quiessence and Multicellularity Team\, IBGC \nThomas Bertero is CRCN CNRS\, CNRS Bronze Medal 2019. He studies the link between the mechanical response of cells to their environment and metabolism.\nInstitut de Pharmacologie moléculaire et cellulaire (IPMC)\nUniversité Côte d’Azur/CNRS/Inserm\nValbonne \nTitle: Mechano-metabolism: From tissues to molecules\n\nAbstract :\nThe spatiotemporal control of cell behaviour requires the transmission of information from the complex structure of tissues to their constituent cells. Mechanotransduction enables this transmission by sensing mechanical environments and adapting cellular behaviours. However\, this process requires energy. Since our pioneering study demonstrating a link between cell mechanics and cell metabolism (Bertero et al\, J Clin Invest 2016) our laboratory has been interested in deciphering how tissue mechanical properties shape – and are shaped by – cell metabolism. Here\, I will summarise our recent discoveries on how the mechanical properties of the tumour niche reprogram glutamine and glucose metabolism to promote breast cancer progression.    \n📆 Wednesday\, May 14\, 3pm\n📌 Amphi BBS (Bordeaux Biologie Santé) 2 rue du Dr Hoffmann Martinot \nSelected publications:\nMechano-dependent sorbitol accumulation supports biomolecular condensate. \nTorrino S\, Oldham WM\, Tejedor AR\, Burgos IS\, Nasr L\, Rachedi N\, Fraissard K\, Chauvet C\, Sbai C\, O’Hara BP\, Abélanet S\, Brau F\, Favard C\, Clavel S\, Collepardo-Guevara R\, Espinosa JR\, Ben-Sahra I\, Bertero T. Cell. 2025 Jan 23;188(2):447-464.e20. doi: 10.1016/j.cell.2024.10.048.   \n\n \nSystems-level regulation of microRNA networks by miR-130/301 promotes pulmonary hypertension. \nBertero T\, Lu Y\, Annis S\, Hale A\, Bhat B\, Saggar R\, Saggar R\, Wallace WD\, Ross DJ\, Vargas SO\, Graham BB\, Kumar R\, Black SM\, Fratz S\, Fineman JR\, West JD\, Haley KJ\, Waxman AB\, Chau BN\, Cottrill KA\, Chan SY. J Clin Invest. 2022 May 16;132(10):e161077. doi: 10.1172/JCI161077.  \n\n \n\n\nMetabo-reciprocity in cell mechanics: feeling the demands/feeding the demand. \nTorrino S\, Bertero T. Trends Cell Biol. 2022 Jul;32(7):624-636. doi: 10.1016/j.tcb.2022.01.013. Epub 2022 Feb 14.   \n \nMechano-induced cell metabolism promotes microtubule glutamylation to force metastasis. \nTorrino S\, Grasset EM\, Audebert S\, Belhadj I\, Lacoux C\, Haynes M\, Pisano S\, Abélanet S\, Brau F\, Chan SY\, Mari B\, Oldham WM\, Ewald AJ\, Bertero T. Cell Metab. 2021 Jul 6;33(7):1342-1357.e10. doi: 10.1016/j.cmet.2021.05.009.  \n \n\n\nTumor-Stroma Mechanics Coordinate Amino Acid Availability to Sustain Tumor Growth and Malignancy. \nBertero T\, Oldham WM\, Grasset EM\, Bourget I\, Boulter E\, Pisano S\, Hofman P\, Bellvert F\, Meneguzzi G\, Bulavin DV\, Estrach S\, Feral CC\, Chan SY\, Bozec A\, Gaggioli C. Cell Metab. 2019 Jan 8;29(1):124-140.e10. doi: 10.1016/j.cmet.2018.09.012.  \n \nVascular stiffness mechanoactivates YAP/TAZ-dependent glutaminolysis to drive pulmonary hypertension. \nBertero T\, Oldham WM\, Cottrill KA\, Pisano S\, Vanderpool RR\, Yu Q\, Zhao J\, Tai Y\, Tang Y\, Zhang YY\, Rehman S\, Sugahara M\, Qi Z\, Gorcsan J 3rd\, Vargas SO\, Saggar R\, Saggar R\, Wallace WD\, Ross DJ\, Haley KJ\, Waxman AB\, Parikh VN\, De Marco T\, Hsue PY\, Morris A\, Simon MA\, Norris KA\, Gaggioli C\, Loscalzo J\, Fessel J\, Chan SY. J Clin Invest. 2016 Sep 1;126(9):3313-35. doi: 10.1172/JCI86387.
URL:https://www.bricbordeaux.com/en/event/invited-seminar-thomas-bertero-14-05-2025/
LOCATION:Salle de conférence BBS (Bordeaux Biologie Santé)\, 2 rue Dr Hoffmann Martinot\, Bordeaux
CATEGORIES:Meetings,Scientific seminars
ATTACH;FMTTYPE=image/jpeg:https://cdn-bricbordeaux.onlc.eu/wp-content/uploads/2025/04/thomas-bertero-2025-05-14.jpg
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=Europe/Paris:20250517T100000
DTEND;TZID=Europe/Paris:20250517T163000
DTSTAMP:20250612T092854Z
CREATED:20250512T092937Z
LAST-MODIFIED:20250612T092854Z
UID:49521-1747476000-1747499400@www.bricbordeaux.com
SUMMARY:2025 Brain Cancer Open House Day
DESCRIPTION:As part of Brain Cancer Awareness Month\, the BRIC is once again organizing its Open House Day on Saturday\, May 17\, 2025\, from 10:00 AM to 4:30 PM\, at its facilities located in Pessac\, on the François Bordes campus (Building B2). \nThis initiative\, fully aligned with the goal of science outreach\, aims to introduce the general public to the daily life of researchers and recent advances in brain cancer research — through engaging\, accessible formats. \nThis free event\, open to everyone\, will feature:\nGuided tours of part of the BRIC’s research labs\nInformation stations with simplified posters\, presented by researchers from Team 1\nMini-seminars\nDiscussions with scientists\, healthcare professionals\, and patient advocacy groups\, including: \nParticipating associations:La Ligue contre le cancer\, Des Étoiles dans la Mer\, ARTC (Association for Brain Tumor Research)\, and ADAM (Association for Children with Medulloblastoma). \nThis initiative is led by Team 1 of the BRIC\, in collaboration with its institutional sponsors (Inserm\, University of Bordeaux\, CNRS) and scientific partners (IBGC and GBMetabo). \n📍 Access: Tram B (François Bordes or Doyen Brus stops) – Free parking nearby (Avenue Léon Duguit\, Pessac)
URL:https://www.bricbordeaux.com/en/event/2025-brain-cancer-open-house-day/
LOCATION:Bâtiment B2\, Allée Geoffroy Saint-Hilaire\, PESSAC\, 33600\, France
CATEGORIES:Meetings
ATTACH;FMTTYPE=image/png:https://cdn-bricbordeaux.onlc.eu/wp-content/uploads/2025/05/portes-ouvertes-17-mai.png
END:VEVENT
END:VCALENDAR